Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 plus anti-EGFR antibody and Pucotenlimab vs investigator’s choice in EGFR-positive esophageal squamous cell carcinoma after failure of first-line therapy
ChiCTR2600121404Phase 2Not yet recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of becotatug vedotin, cetuximab and pucotenlimab in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: Objective response rate (ORR). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
becotatug vedotincetuximabpucotenlimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600121404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121404.